M Feldhahn

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Aim: Knowledge about somatic driver mutations in cancer is crucial for decision-making in personalized therapy. Samples with low tumor content cannot be sequenced reliably with traditional methods. We have developed a complete pipeline to sequence more than 550 cancer-relevant genes in parallel using next-generation sequencing of FFPE or frozen tumor(More)
  • 1